HomeAI · summaries
Storia in 3 fonti
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to potentially introduce three new drugs to the market within the next 12 months | As BridgeBio ramps up for the launch of three new medicines and continues to channel resources into its soon-to-be-blockbuster in ATTR-CM, Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Zymeworks acquires struggling Theravance for $929M
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up…
- ·
biopharmadive.com
BridgeBio gets funding for drug launch; United buys into cell therapy
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
